William Symonds

Novel Four‐Drug Salvage Treatment Regimens after Failure of a Human Immunodeficiency Virus Type 1 Protease Inhibitor–Containing Regimen: Antiviral Activity and Correlation of Baseline Phenotypic Drug Susceptibility with Virologic Outcome

Steven G. Deeks, Nicholas S. Hellmann, Robert M. Grant et al. · The Journal of Infectious Diseases · 1999 · 169 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Use of Drug Effect Interaction Modeling with Monte Carlo Simulation To Examine the Impact of Dosing Interval on the Projected Antiviral Activity of the Combination of Abacavir and Amprenavir

George L. Drusano, David Z. D’Argenio, Sandra L. Preston et al. · Antimicrobial Agents and Chemotherapy · 2000 · 59 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Undetectable Cerebrospinal Fluid HIV RNA and β-2 Microglobulin Do Not Indicate Inactive AIDS Dementia Complex in Highly Active Antiretroviral Therapy-Treated Patients

Lucette A. Cysique, Bruce J. Brew, Mark Halman et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2005 · 56 citations

Medicine, Immunology, Neurology +15

Factors in AIDS Dementia Complex Trial Design: Results and Lessons from the Abacavir Trial

Bruce J. Brew, Mark Halman, José Catalán et al. · PLoS Clinical Trials · 2007 · 55 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Nucleoside Analog 1592U89 and Human Immunodeficiency Virus Protease Inhibitor 141W94 Are Synergistic In Vitro

George L. Drusano, David Z. D’Argenio, William Symonds et al. · Antimicrobial Agents and Chemotherapy · 1998 · 49 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17